Drug-DNA Interaction Protocols
The last few years have witnessed the creation of new generations of sequence reading compounds, which have incredible potential for targeting specific DNA sequences. In Drug-DNA Interaction Protocols, Second Edition, expert researchers explore these comp
- PDF / 16,289,396 Bytes
- 320 Pages / 504 x 720 pts Page_size
- 91 Downloads / 205 Views
in
Molecular Biology™
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For other titles published in this series, go to www.springer.com/series/7651
Drug-DNA Interaction Protocols Second Edition
Edited by
Keith R. Fox School of Biological Sciences, University of Southampton, Southampton, UK
Editor Keith R. Fox School of Biological Sciences University of Southampton Southampton UK [email protected]
ISSN 1064-3745 e-ISSN 1940-6029 ISBN 978-1-60327-417-3 e-ISBN 978-1-60327-418-0 DOI 10.1007/978-1-60327-418-0 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2009940801 © Humana Press, a part of Springer Science+Business Media, LLC 1998, 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Cover illustration: Background art is derived from Figure 6 in Chapter 9. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface DNA has been known to be the cellular target for many cytotoxic anticancer agents for several decades. The knowledge of its structure in atomic detail and the ease with which DNA fragments (both synthetic oligonucleotides and natural sequences) can be prepared and manipulated has aided the design of compounds that bind to it with improved selectivity. On the basis of this information, new generations of sequence reading compounds (including triplex forming oligonucleotides and minor groove binding ligands) have been prepared, which have the potential for targeting specific DNA sequences as anti-gene agents. Within the last 10 years, it has also become apparent that the familiar DNA duplex is not the only structure that can be targeted by DNA-binding ligands and there has been increased interest in triplex and quadruplex structures as drug targets, as well as proteinDNA complexes, such as those with nucleosomes or topoisomerases. Each of these advances has required the availability and development of an arsenal
Data Loading...
